The fate of (−)1-(benzofuran-2-yl)-2-propylaminopentane · HCl, (−)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain

@article{Magyar2010TheFO,
  title={The fate of (−)1-(benzofuran-2-yl)-2-propylaminopentane · HCl, (−)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain},
  author={K. Magyar and J. Lengyel and A. Bolehovszky and B. Knoll and Iidik{\'o} Miklya and J. Knoll},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  year={2010},
  volume={27},
  pages={157-161}
}
  • K. Magyar, J. Lengyel, +3 authors J. Knoll
  • Published 2010
  • Chemistry, Medicine
  • European Journal of Drug Metabolism and Pharmacokinetics
  • SummaryOur aim was to study the fate of (−)-1-(benzofuran-2-yl)-2-propylaminopentane · HCl [(−)-BPAP] in rats, using radio-labelled compound [(−)-BPAP-14C]. Radioactivity was measured by liquid scintillation technique and the tissue concentrations of radioactivity were calculated on the basis of the specific activity of (−)-BPAP-14C and the values are given in ngeq./g.Radioactivity was well absorbed after i.p., s.c. and oral treatment and Cmax has been reached at 30 to 60 min following drug… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 10 REFERENCES
    -)Deprenyl and (-) l-phenyl-z-propylaminopentane, [(-)pPAP]. act primarily as potent stimulants of action potential- transmitter release coupling in the catecholaminergic neurones
    • 1996
    Deprenyl : the anti - aging psychoenergizer
    • 2001
    Outlines of a drug strategy to slow brain aging
    • 2000